title: [Erectile dysfunction evaluation after brachytherapy for low risk prostate adenocarcinoma: prospective study of patients with a baseline IIEF5>16].
abstract: OBJECTIVE
  To evaluate erectile function (EF) prospectively from 1 to 2 years post-brachytherapy in patients with a baseline IIEF5 score>16.
  
  
  METHODS
  Between 2007 and 2012, 179 patients underwent an exclusive brachytherapy for localised low risk prostate adenocarcinoma. Neo-adjuvant hormotherapy (15.6%) and post-brachytherapy intake phosphodiesterase inhibitors (PDE5i) were not considered as exclusion criteria. EF was evaluated via a scoring questionnaire IIEF5 before the surgical implantation, at month 12 and 24 post-operation. Only patients with an initial IIEF5 score>16 were included.
  
  
  RESULTS
  Of the 179 patients, 102 (57%) had a baseline IIEF5>16. At 12 months, 51.1% maintained an IIEF5>16 and 24.5% had a mild to moderate erectile dysfunction (ED), so that a total of 75.6% with IIEF5≥12. About 18% of patients had used PDE5i. At 24 months, 53.2% had an IIEF5>16 and 80.6% had an IIEF5≥12. Severe ED was reported in only 14.5% of the patients. The mean IIEF5 was 16.2 with an average decline of 5 points from the initial stage. All patients who were treated with PDE5i (27%) could have sexual intercourse. EF at baseline was reported as the only predictive factor of ED in multivariate analysis, 70% of patient without ED initially, had an IIEF5>16 at 1 and 2 years.
  
  
  CONCLUSIONS
  Severe ED was quite rare (14%) during the first 2 years post-brachytherapy and more than half of patients maintained an IIEF5>16. The main predictive factor was the erectile function at baseline.
  
  
  METHODS
  4.
authors.affiliation: Service d'urologie, CHU de Brest, 29200 Brest, France; Faculté de médecine et des sciences de la santé, université de Brest, 29200 Brest, France; Université européenne de Bretagne, 29200 Brest, France. Electronic address: f.delage@hotmail.fr.
authors.forename: F
authors.initials: F
authors.lastname: Delage
authors.affiliation: Service d'urologie, CHU de Brest, 29200 Brest, France; Faculté de médecine et des sciences de la santé, université de Brest, 29200 Brest, France; Université européenne de Bretagne, 29200 Brest, France. Electronic address: marie-aimee.perrouin-verbe@chu-brest.fr.
authors.forename: M-A
authors.initials: MA
authors.lastname: Perrouin-Verbe
authors.affiliation: Service de radiothérapie, CHU de Brest, 29200 Brest, France; Faculté de médecine et des sciences de la santé, université de Brest, 29200 Brest, France; Université européenne de Bretagne, 29200 Brest, France. Electronic address: emmanuelle.lefur@chu-brest.fr.
authors.forename: E
authors.initials: E
authors.lastname: Le Fur
authors.affiliation: Service d'urologie, CHU de Brest, 29200 Brest, France; Faculté de médecine et des sciences de la santé, université de Brest, 29200 Brest, France; Université européenne de Bretagne, 29200 Brest, France. Electronic address: gregory.papin@chu-brest.fr.
authors.forename: G
authors.initials: G
authors.lastname: Papin
authors.affiliation: Service d'urologie, CHU de Brest, 29200 Brest, France; Faculté de médecine et des sciences de la santé, université de Brest, 29200 Brest, France; Université européenne de Bretagne, 29200 Brest, France. Electronic address: maxime.thoulouzan@chu-brest.fr.
authors.forename: M
authors.initials: M
authors.lastname: Thoulouzan
authors.affiliation: Service de radiothérapie, CHU de Brest, 29200 Brest, France. Electronic address: jean-pierre.malhaire@chu-brest.fr.
authors.forename: J-P
authors.initials: JP
authors.lastname: Malhaire
authors.affiliation: Service de radiothérapie, CHU de Brest, 29200 Brest, France; Faculté de médecine et des sciences de la santé, université de Brest, 29200 Brest, France; Université européenne de Bretagne, 29200 Brest, France. Electronic address: olivier.pradier@chu-brest.fr.
authors.forename: O
authors.initials: O
authors.lastname: Pradier
authors.affiliation: Service d'urologie, CHU de Brest, 29200 Brest, France; Faculté de médecine et des sciences de la santé, université de Brest, 29200 Brest, France; Université européenne de Bretagne, 29200 Brest, France; CeRePP, hôpital Pitié-Salpétrière, 75013 Paris, France. Electronic address: georges.fournier@chu-brest.fr.
authors.forename: G
authors.initials: G
authors.lastname: Fournier
authors.affiliation: Service d'urologie, CHU de Brest, 29200 Brest, France; Faculté de médecine et des sciences de la santé, université de Brest, 29200 Brest, France; Université européenne de Bretagne, 29200 Brest, France; CeRePP, hôpital Pitié-Salpétrière, 75013 Paris, France. Electronic address: antoine.valeri@chu-brest.fr.
authors.forename: A
authors.initials: A
authors.lastname: Valéri
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy*; D001918:Brachytherapy / Q000009:adverse effects*; D007172:Erectile Dysfunction / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010410:Penile Erection / Q000502:physiology; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D018570:Risk Assessment
keywords: Brachytherapy; Cancer; Curiethérapie; Dysfonction érectile; Erectile dysfunction; Erection; IIEF5; Prostate; Érection